Neonatal encephalopathy is a syndrome of disturbed neurological function during the first days of life. Newborns may show abnormal consciousness, poor muscle tone, weak reflexes, seizures, difficulties with breathing or problems feeding. Hypoxic-ischemic injury, caused by insufficient oxygen and blood flow to the brain, is one important cause, but infection, inflammation, metabolic disorders, stroke, genetic disease and other conditions can produce similar signs. For that reason, the term “hypoxic-ischemic encephalopathy,” or HIE, should not automatically be applied to every infant with neonatal neurological dysfunction.

The urgency of assessing severity increased after therapeutic hypothermia became standard care for selected infants with moderate to severe HIE. Cooling the newborn to approximately 33–34 degrees Celsius for about 72 hours can reduce secondary brain injury when it is initiated within the first six hours after birth. Yet the criteria used to determine eligibility are based largely on early clinical observations, blood-gas measurements, neurological examinations and evidence of a difficult birth. These indicators are valuable, but they are snapshots taken during a rapidly changing process. A newborn who appears severely impaired immediately after delivery may improve quickly, while another with initially subtle signs may deteriorate as cellular injury evolves.

Clinical grading systems are therefore central to neonatal care, but they have limits. Common examinations assess consciousness, spontaneous activity, posture, muscle tone, primitive reflexes, autonomic function and seizures. These domains help clinicians distinguish degrees of encephalopathy, but they are influenced by gestational age, medication, sedation, pain, respiratory support, temperature and the infant’s general medical condition. Premature infants may display neurological signs that differ from those of term newborns, and an examination performed shortly after resuscitation may not reflect the infant’s eventual neurological state.

The article’s central message is that severity should be understood as a multidimensional and time-dependent measurement rather than a single label. The brain injury process can include an initial period of energy failure, a temporary phase of partial recovery and a later wave of secondary damage involving excitotoxicity, oxidative stress, inflammation, mitochondrial dysfunction and cell death. Because these processes unfold over hours and days, severity cannot always be captured accurately by one examination at one moment. Repeated assessments may reveal a trajectory, showing whether neurological function is recovering, remaining stable or worsening.

Electroencephalography and amplitude-integrated electroencephalography offer one way to observe this trajectory. These techniques record the brain’s electrical activity and can identify abnormal background patterns, reduced variability and seizures that may not produce visible movements. Electrographic seizures are particularly important because newborns can have “electroclinical dissociation,” in which abnormal electrical activity continues even after outward signs disappear. A persistently severely abnormal background pattern may indicate substantial cerebral dysfunction, whereas normalization over time can provide evidence of neurological recovery. However, interpretation requires expertise, and electrical patterns can be affected by anticonvulsant medication and other treatments.

Brain imaging adds another layer of information. Magnetic resonance imaging, especially diffusion-weighted imaging and magnetic resonance spectroscopy, can reveal patterns of injury in the basal ganglia, thalamus, watershed regions and white matter. Diffusion abnormalities may emerge early as injured cells lose the ability to regulate water movement, while later scans can show the established distribution and extent of damage. Magnetic resonance spectroscopy can provide metabolic information, including changes in lactate and other chemical signals associated with impaired energy production. Imaging is not a perfect crystal ball, however: timing matters, findings can evolve, and the relationship between a scan and an individual child’s developmental outcome is probabilistic rather than absolute.

Biomarkers from blood, urine or cerebrospinal fluid are also being investigated as tools for refining severity assessment. Molecules such as neuron-specific enolase, S100 calcium-binding protein B, glial fibrillary acidic protein and ubiquitin C-terminal hydrolase-L1 may rise when neurons or glial cells are damaged. Other candidates reflect inflammation, oxidative stress, mitochondrial injury or disruption of the blood-brain barrier. The attraction of biomarkers is clear: a rapid laboratory test could complement bedside examination and potentially identify hidden injury. But biological markers can be influenced by organ failure, infection, prematurity and the timing of sample collection. Most remain research tools rather than stand-alone tests for making high-stakes decisions.

Arnáez also highlights a fundamental problem in neonatal research: severity is often defined differently from one study to another. One investigation may use the initial neurological examination, another may classify infants according to cooling eligibility, and a third may rely on MRI, seizure burden or developmental outcomes at 18 or 24 months. These definitions are related, but they are not interchangeable. If studies enroll different populations under the same label of “moderate encephalopathy,” comparisons become difficult and the apparent effectiveness of treatments may be distorted. More consistent severity frameworks could improve clinical trials by allowing researchers to determine which infants benefit from an intervention, at what stage and under which biological conditions.

A more precise approach would combine several forms of evidence: perinatal history, early and repeated neurological examinations, continuous brain monitoring, neuroimaging, laboratory biomarkers and carefully selected developmental outcomes. Such a model would not replace clinical judgment or reduce an infant to a numerical score. Instead, it would recognize that neonatal encephalopathy is a dynamic syndrome with different causes, injury patterns and recovery pathways. The most useful measure of severity may ultimately be a profile that describes the infant’s current neurological state, the likely mechanism of injury and the direction of change over time.

This shift could also improve communication with families. A label such as “mild encephalopathy” may sound reassuring even though some infants with initially mild signs later develop seizures, developmental delays or learning difficulties. Conversely, an early severe presentation does not make an individual outcome inevitable. Families need explanations that acknowledge uncertainty while describing the evidence emerging from examinations, monitoring and imaging. Prognosis should be updated as new information becomes available, rather than being fixed by a single early assessment.

The broader significance extends beyond neonatal intensive care. Better measurement could support trials of treatments that complement cooling, including strategies aimed at reducing inflammation, stabilizing mitochondrial function, controlling seizures or promoting repair. It could also help distinguish infants with genuine hypoxic-ischemic injury from those whose encephalopathy has another cause, ensuring that therapies are tested in biologically appropriate groups. The challenge is to develop tools that are reliable across hospitals, practical during the narrow window when treatment can help and validated against meaningful long-term outcomes.

Neonatal encephalopathy is therefore moving from a diagnostic label toward a measurable process. The categories of mild, moderate and severe remain useful for urgent clinical decisions, but they are only the starting point. A combination of serial examinations, brain activity monitoring, imaging and molecular evidence may provide a more accurate account of what is happening inside the newborn brain. By looking beyond definitions, clinicians and researchers may be better equipped to identify injury early, tailor treatment and understand why infants with apparently similar beginnings can follow very different developmental paths.

Subject of Research: Measuring severity, prognosis and biological progression in neonatal encephalopathy.

Article Title: Beyond definitions: measuring severity in neonatal encephalopathy

Article References:

Arnáez, J. Beyond definitions: measuring severity in neonatal encephalopathy. Pediatr Res (2026). https://doi.org/10.1038/s41390-026-05378-6

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41390-026-05378-6

Keywords: neonatal encephalopathy, hypoxic-ischemic encephalopathy, neonatal brain injury, therapeutic hypothermia, neuroimaging, electroencephalography, biomarkers, neonatal neurology, prognosis, newborn health

Neonatal encephalopathy, a syndrome marked by disturbed neurological function in the earliest days of life, remains a significant cause of morbidity and mortality worldwide. Its multifactorial origins encompass hypoxic-ischemic insults during birth that precipitate brain injury through complex biochemical cascades. Diagnosing the severity and predicting long-term outcomes have traditionally relied on clinical evaluation and MRI, but these approaches often fall short in the critical early hours when rapid decisions are paramount. Against this backdrop, the search for early, reliable biomarkers is not only urgent but essential.

The study pivots on the premise that lactate, a byproduct of anaerobic metabolism, offers a window into the evolving state of cerebral injury. Elevated blood lactate levels are a recognized hallmark of tissue hypoxia and metabolic distress. However, it is the kinetics—the temporal changes and clearance rates of lactate—that offer a more dynamic and informative perspective than static measurements. By meticulously tracking lactate levels in neonates diagnosed with NE, the researchers mapped these kinetic profiles against the quantitative severity of brain injury as assessed by advanced MRI techniques.

Their methodological rigor involved longitudinal sampling of blood lactate levels at defined intervals post-birth, paired with high-resolution MRI scans interpreted through validated scoring systems of brain damage. This integrative approach ensured that findings were anchored in both biochemical and structural domains. Importantly, the kinetic patterns revealed striking associations: neonates exhibiting rapid clearance of blood lactate tended to have milder MRI-detected brain injuries, while those with persistently high or rising lactate profiles showed significantly more severe damage characterized by diffusion restrictions and cortical abnormalities.

Delving into the biochemical underpinnings, the research highlights the shift from aerobic to anaerobic metabolism within compromised cerebral tissue, a hallmark of hypoxic injury. This metabolic switch results in lactate accumulation not only locally within the brain but systemically, reflecting the degree and persistence of ischemic stress. The newborn’s ability to clear this lactate correlates with the restoration of metabolic homeostasis and, by extension, the potential for neuroprotection and recovery. Such insights elevate lactate kinetics from a mere laboratory value to a potent, real-time indicator of neurophysiological status.

Clinically, these findings usher in a paradigm where bedside blood sampling for lactate can complement neuroimaging to refine prognostic accuracy dramatically. Early interventions, including hypothermia treatment—a neuroprotective strategy already in use—may be more precisely timed and tailored based on biomarker profiles, potentially improving neurodevelopmental outcomes. This biomarker-driven approach could mitigate the reliance on delayed imaging and subjective clinical assessments alone.

Moreover, the study’s implications resonate beyond immediate diagnostics. Understanding lactate kinetics opens avenues for therapeutic innovation targeting metabolic pathways during the acute injury phase. Pharmacological agents aimed at facilitating lactate clearance or modulating metabolic responses could emerge as adjunct therapies, enhancing established treatments. Future clinical trials inspired by these findings are poised to explore such interventions, representing a thrilling frontier in neonatal neurocritical care.

The integration of metabolic data with structural imaging also exemplifies the power of multimodal monitoring. By correlating biochemical markers with MRI-based brain injury scales, the research provides a robust framework for objective and reproducible assessment. This not only enhances clinical practice but also strengthens the scientific foundation for understanding NE pathophysiology, a critical step in overcoming the complexities of this devastating condition.

Importantly, the study acknowledges the heterogeneity of neonatal encephalopathy, influenced by variables such as gestational age, birth complications, and comorbidities. The nuanced interpretation of lactate kinetics must therefore be contextually informed, promoting personalized medicine approaches. The authors stress that while promising, these biomarkers should be integrated within a broader diagnostic algorithm incorporating clinical judgment and comprehensive neuroimaging.

Technical advancements underpinning this research were pivotal—the precision of lactate assays, the timing of blood draws, and the sophistication of MRI modalities such as diffusion tensor imaging enabled the nuanced detection of injury severity. Such technological synergies illustrate the evolving landscape of neonatal diagnostics, where physiology and imaging converge in unparalleled detail.

Beyond the individual neonate, implications extend to healthcare systems globally. Early, accurate prognostic biomarkers like lactate kinetics could optimize resource allocation, prioritize high-risk patients for intensive care, and inform parental counseling with greater confidence. This efficiency is especially vital in resource-limited settings where MRI availability is constrained, as blood lactate measurement is widely accessible and cost-effective.

The study also invites reflection on the broader concept of biochemical kinetics as biomarkers. Lactate kinetics in NE sets a precedent for investigating dynamic metabolic parameters in other acute neonatal conditions or pediatric neurological disorders. The paradigm shift emphasizes the temporal evolution of biomarkers over single static values, enriching the arsenal of diagnostic tools in critical care.

In sum, the compelling evidence linking blood lactate kinetics to MRI-defined brain injury severity in neonatal encephalopathy represents a major stride forward. Bassani and colleagues’ research transcends traditional diagnostic boundaries, interweaving metabolic and structural insights to furnish clinicians with a potent, early biomarker. This innovation holds profound potential for enhancing prognostic precision, guiding treatment decisions, and ultimately improving neurodevelopmental outcomes in vulnerable newborns.

As neonatal intensive care continues to evolve, such integrative biomarker strategies exemplify the cutting-edge fusion of clinical biochemistry and neuroimaging. The clinical community anticipates that ongoing validation and expansive trials will cement blood lactate kinetics as a standard tool in the management of neonatal encephalopathy, transforming care pathways and offering renewed hope for affected families worldwide. This research marks an exhilarating advancement in the quest to decode the complex metabolic signatures of brain injury and harness them for healing.

Subject of Research: Neonatal encephalopathy, blood lactate kinetics, MRI brain injury

Article Title: Blood Lactate Kinetics as Biomarkers of MRI Brain Injury in Neonatal Encephalopathy

Article References:
Bassani, G., Décaillet, M., Hagmann, P. et al. Blood lactate kinetics as biomarkers of MRI brain injury in neonatal encephalopathy. Pediatr Res (2026). https://doi.org/10.1038/s41390-026-04822-x

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41390-026-04822-x

HIE’s clinical challenge stems from its insidious onset and the subtlety of early cerebral changes. While it is established that cerebral blood flow (CBF) alterations play a pivotal role in the progression of HIE, the specific patterns, especially in the initial hours post-insult, have remained poorly defined due to limitations inherent in conventional imaging modalities. Zhao and colleagues, in a state-of-the-art study published in Pediatric Research, harness the potential of an advanced multi-angle plane wave ultrafast Doppler system—capable of capturing cerebral perfusion and venous drainage in exquisite detail and temporal resolution—to delineate these early hemodynamic shifts in a neonatal rat model.

Ultrafast Doppler imaging represents a technological revolution in neurovascular visualization. Unlike conventional Doppler ultrasound, which emits waves sequentially at relatively low frame rates, HF-μDoppler employs weak plane waves from multiple angles to reconstruct an entire imaging plane with a staggering frame rate of several thousand frames per second. This approach not only enhances signal-to-noise ratio but also dramatically improves sensitivity to slow-moving blood flow in tiny neonatal cerebrovascular structures. The study capitalizes on these technical advantages to map CBF and cerebral venous drainage (CVD) in real-time with remarkable spatial and temporal fidelity, empowering researchers to observe pathophysiological changes as they unfold.

In Zhao et al.’s model, newborn rat pups subjected to controlled hypoxic-ischemic insults revealed distinctive alterations in both arterial and venous cerebral circulation within minutes to hours after injury onset. This temporal resolution illuminates a critical period where therapeutic interventions could be most efficacious but are typically missed due to diagnostic delays. The ultrafast Doppler imaging delineated a pronounced reduction in arterial CBF in key brain regions implicated in motor and cognitive function, accompanied paradoxically by disrupted venous drainage patterns. These findings elucidate a dynamic vascular response characterized by a complex interplay between impaired perfusion and venous outflow obstruction.

The intricacies uncovered in cerebral venous drainage bear special significance. Previously, most research and clinical focus remained on arterial supply disruption; however, venous congestion or stasis can exacerbate brain edema and secondary injury cascades. The study’s ability to visualize compromised cerebral venous outflow provides a missing piece in understanding HIE pathophysiology and highlights the potential of venous metrics as early prognostic markers. Such comprehensive hemodynamic profiling extends beyond morphology, offering functional insights crucial for precision medicine approaches in neonatal neurocritical care.

From a technical perspective, the ultrafast Doppler system utilized in this study integrates multi-angle plane wave sequences that yield compounded acquisitions, enhancing spatial resolution without sacrificing temporal acuity. This method excels in detecting microvascular flow patterns that escape detection by traditional color Doppler or MRI modalities, especially within the fragile neonatal brain where motion artifacts and limited acoustic windows pose formidable challenges. The authors meticulously optimized the transducer frequency and imaging protocols to balance penetration depth with sensitivity, setting a benchmark for future preclinical and clinical investigations.

The implications of this research transcend the laboratory bench, potentially reshaping clinical paradigms in neonatal intensive care units worldwide. Early, non-invasive, bedside assessment of cerebral hemodynamics using ultrafast Doppler could transform the diagnostic timeline for HIE, enabling clinicians to tailor neuroprotective strategies more effectively. Prompt identification of altered CBF and CVD patterns would facilitate timely administration of hypothermia or emerging pharmacologic interventions, thereby mitigating irreversible neuronal damage and improving neurodevelopmental outcomes.

Moreover, the study fuels a broader conversation about the integration of advanced imaging technologies in neonatal neurology. The capability to monitor neurovascular health dynamically paves the way for real-time surveillance of cerebral autoregulation, enabling therapeutic adjustments responsive to fluctuating cerebral perfusion pressures. This represents an evolution from snapshot diagnostics to continuous functional monitoring, aligning with the principles of precision neonatology and individualized care.

In addition to diagnostic utilities, the granularity of data obtained through HF-μDoppler imaging offers rich avenues for exploring the mechanisms underpinning HIE-induced brain injury. By charting temporal vascular responses, researchers can dissect how ischemia and hypoxia disrupt neurovascular coupling, influence blood-brain barrier integrity, and provoke inflammatory cascades. This mechanistic insight could guide the design of novel therapeutics targeting specific vascular dysfunctions, complementing existing neuroprotective modalities.

Critically, while the neonatal rodent model provides valuable translational insights, the authors acknowledge the challenges inherent in extrapolating these findings directly to human neonates. Differences in cerebral anatomy, developmental timelines, and injury response necessitate rigorous validation in clinical trials. Nevertheless, the technical framework and neurovascular signatures identified constitute a robust foundation for such endeavors, accelerating progress toward clinically deployable ultrafast Doppler imaging platforms adapted for neonates.

The study’s emphasis on cerebral venous drainage patterns also prompts a paradigm shift in clinical assessments. Traditionally overshadowed by arterial considerations, venous hemodynamics could emerge as a vital biomarker for both diagnosis and prognostication in HIE. This expanded vascular perspective encourages multidisciplinary collaboration between neurologists, radiologists, and neonatologists to refine imaging protocols and integrate venous flow analysis into routine neonatal brain assessments.

Furthermore, the availability of ultrafast Doppler imaging as a portable, cost-effective technology suits its application in diverse healthcare settings. Unlike MRI, which is costly and often requires sedation, HF-μDoppler offers a bedside, real-time assessment with minimal risk, increasing accessibility in resource-limited environments where HIE incidence remains disproportionately high. Such democratization of advanced neuroimaging could substantially narrow disparities in neonatal care outcomes globally.

Zhao and colleagues have thus opened a new frontier in neonatal brain monitoring, demonstrating how innovations in ultrafast ultrasound imaging can translate complex cerebral hemodynamics into actionable clinical information. Their findings not only enrich our understanding of HIE pathophysiology but also herald a future where early diagnosis and tailored interventions radically improve survival and quality of life for affected newborns.

Looking ahead, integrating ultrafast Doppler data with other multimodal neuromonitoring techniques, such as near-infrared spectroscopy and electroencephalography, could yield synergistic insights, forming comprehensive neurovascular profiles. This holistic approach will deepen the understanding of neonatal brain injury and recovery processes, ultimately guiding personalized therapeutic regimens.

The study’s impact is further amplified by its potential to accelerate drug development. By providing reliable biomarkers of cerebral perfusion and venous drainage integrity, HF-μDoppler imaging can serve as a sensitive endpoint in preclinical trials of neuroprotective agents, optimizing dosage and treatment timing. Such translational pathways promise to bring effective therapies from bench to bedside with greater speed and precision.

In sum, this pioneering research stands at the crossroads of technology and neonatal neuroscience, exemplifying how high-frequency ultrafast Doppler imaging can revolutionize our approach to one of the most challenging neonatal brain disorders. As the technology matures and enters clinical practice, it holds the promise to transform outcomes for thousands of newborns worldwide, offering hope where it has long been elusive.

Subject of Research: Early cerebral blood flow and cerebral venous drainage patterns in hypoxic-ischemic encephalopathy, evaluated using high-frequency ultrafast Doppler imaging in a neonatal rat model.

Article Title: Ultrafast ultrasound imaging reveals altered cerebral blood flow in newborn rats with hypoxic-ischemic encephalopathy.

Article References:
Zhao, Y., Zhang, J., Xia, Q. et al. Ultrafast ultrasound imaging reveals altered cerebral blood flow in newborn rats with hypoxic-ischemic encephalopathy. Pediatr Res (2025). https://doi.org/10.1038/s41390-025-04275-8

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41390-025-04275-8